BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-amylyx-avexitide-lucidity-q3-2026@catalyst-calendar.local
DTSTAMP:20260720T200547Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:Amylyx avexitide LUCIDITY三期PBH顶线数据读出窗口
DESCRIPTION:Amylyx披露avexitide治疗胃旁路术后低血糖的Phase 3 LUCIDITY研究已完成入组，顶线数据预计在2026年第三季度公布。\\nImpact score: 66\\nExpected: 读出将影响GLP-1受体拮抗剂在PBH罕见内分泌适应症中的注册可行性和Amylyx转型预期。\\nAffected: AMLX(subject\, unknown\, score 78)\; XBI(etf\, mixed\, score 44)\; LLY(theme\, unknown\, score 32)\\nSources: Amylyx enrollment completion: https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-completion-of-enrollment-in-pivotal-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia\\nAmylyx Q1 2026 update: https://www.amylyx.com/news/amylyx-pharmaceuticals-reports-first-quarter-2026-financial-results\\nClinicalTrials.gov LUCIDITY: https://clinicaltrials.gov/study/NCT06747468\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-amylyx-avexitide-lucidity-q3-2026
CATEGORIES:guidance\,US\,clinical readout\,Phase 3\,PBH\,GLP-1 antagonist
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Amylyx avexitide LUCIDITY三期PBH顶线数据读出窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Amylyx avexitide LUCIDITY三期PBH顶线数据读出窗口
END:VALARM
END:VEVENT
END:VCALENDAR